Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
Archer. DF, et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19(6):622-9.
Archer DF. Estradiol Gel: a new option in hormone replacement therapy. OBG Management. 2004:46-66.
Panay N, et al. The 2013 British Menopause Society & Women’s Health Concern. Recommendations on hormone replacement therapy. Menopause Int. 2013;19(2):59-68.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-753.
Baber RJ, et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109-150.
Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-753.
Bergendal A, et al. Riesgo de tromboembolia venosa asociada con el uso local y sistémico de terapia hormonal en mujeres peri y postmenopáusicas y en relación con el tipo y la vía de administración. Menopause. 2016;23(6):593-9.
Canonico M, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006;4(6):1259-65.
